Related Experiment Videos

Clinician update: direct thrombin inhibitors in acute coronary syndromes

Joanna J Wykrzykowska1, Sekar Kathiresan, Ik-Kyung Jang

  • 1Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

Journal of Thrombosis and Thrombolysis
|October 24, 2003
PubMed

Insights

Direct thrombin inhibitors (DTIs) offer safer anticoagulation for acute coronary syndromes (ACS) than unfractionated heparin (UFH). Renewed interest in DTIs like hirudin, bivalirudin, and argatroban is driven by improved understanding of their use.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Antithrombotic therapy is crucial for atherosclerotic cardiovascular disease.
  • Unfractionated heparin (UFH) is a traditional but limited thrombin inhibitor.
  • Direct thrombin inhibitors (DTIs) offer potential advantages over UFH.

Purpose of the Study:

  • To review clinical studies on DTIs in acute coronary syndromes (ACS).
  • To assess the efficacy and safety of hirudin, bivalirudin, and argatroban.
  • To explore the renewed interest in DTIs following initial disappointing results.

Main Methods:

  • Review of clinical studies involving hirudin, bivalirudin, and argatroban.
  • Analysis of DTIs in the context of acute myocardial infarction (AMI), unstable angina (UA), and percutaneous coronary interventions (PCI).
  • Evaluation of anticoagulation predictability and safety profiles.

Main Results:

  • Initial studies of DTIs in the early 1990s yielded disappointing outcomes.
  • Advancements in understanding DTI usage have led to renewed clinical interest.
  • DTIs demonstrate potential for more efficient clot-bound thrombin inactivation.

Conclusions:

  • DTIs show promise for improved anticoagulation in ACS patients.
  • Further understanding of DTI application is critical for optimal patient outcomes.
  • Hirudin, bivalirudin, and argatroban warrant continued investigation in cardiovascular settings.

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...